Nervous Disorder TRIZ Cases

Administering recombinant annexin A6 mediates membrane repair in cardiomyocytes, reducing cellular injury markers like LDH and troponin release.

Selective morphinan analogs engage peripheral opioid receptors to provide effective pain relief while minimizing central nervous system side effects.

MSC spheroids reduce pulmonary accumulation during intravenous injection, extending survival time and improving therapeutic efficacy.

A synergistic nutrient blend activates TFEB downstream genes to support cognitive and emotional health.

A method inserts the PU.1 transcription factor into genomic safe harbor sites to produce pure microglia from stem cells.

Neonatal rAAV delivery of eEF1A2 overcomes blood-brain barrier complexity, improving survival and motor function in neurological disease models.

Fatty acid-modified xenin peptide analogues reduce amyloid plaque formation while avoiding adverse effects of secretase inhibitors.

Non-ionic contrast agents transport antisense oligonucleotides across the blood-brain barrier.

A transmucosal film uses permeation enhancers to increase drug absorption rates across biological membranes.

Compounds inhibit STING receptors to suppress aberrant immune signaling, resolving inflammatory disorders like SAVI without compromising protective immunity.

Co-expressing SUMF1 in CHO-K1 cells generates active phosphorylated GALNS, reducing immunogenicity while boosting yield.

Dynamic temperature control suppresses proliferation during hibernation, resolving the contradiction between automation and precise cell number management.

Isolating CD133+CD24+ kidney stem cells enables targeted regeneration of damaged renal tissue, replacing costly dialysis and transplant procedures.

PFAR-inhibiting compounds reduce ribosome chaperone activity, addressing the trade-off between therapeutic efficacy and off-target toxicity in proteinopathies.

Deimmunized anti-human CD40 monoclonal antibodies reduce immunogenicity while maintaining binding activity.

Formula I compounds bind the ORL-1 receptor to treat insomnia without causing addiction or impacting liver function.

Anti-CGRP receptor antibodies selectively block the CGRP pathway, avoiding intolerable side effects from conventional prophylactics like topiramate.

Agonistic anti-TREM2 antibodies restore microglial function by increasing CSF1R expression, addressing underlying deficiencies in leukoencephalopathy.

A senotherapeutic substance combining flavonoids and fatty acids to eliminate senescent cells.

Bioconverted noni and calamansi extracts lower cortisol secretion to relieve stress without pharmaceutical side effects.

Nerve growth factor fusion protein extends half-life over 17 times by leveraging IgG recycling, reducing administration frequency and adverse reactions.

Optimizing the CBD to THC ratio within an 18:1 to 30:1 range resolves the contradiction between effective pain relief and opioid side effects.

Homotaurine analogs decrease glutamatergic signaling intensity, addressing ineffective current treatments and improving social behavior in autism patients.

Multi-targeting siRNA molecules combine cleavage and translational suppression pathways to achieve potent gene down-regulation.

Novel hydroxysteroids activate AMP kinase to stimulate mitochondrial biogenesis.

Inert atmosphere processing of choline ellagate prevents amine odor formation while maintaining stability and bioavailability.

An injection spring drives a piston rod to move a stopper within a syringe barrel.

A traditional Chinese medicinal composition reduces lung tissue edema in neurogenic pulmonary edema models.

Baseline and post-administration CRH measurements determine treatment responsiveness within hours, avoiding months of ineffective therapy.

Combining bupropion metabolites with dextromethorphan inhibits rapid hepatic clearance, sustaining therapeutic plasma levels in extensive metabolizers.

Extracted CBDV and CBDVA mitigate neuronal death and inflammation without the side effects of crude plant extracts.

Isolating binding molecules from stable individuals to target pathological protein variants.

Segmenting Parkinson's patients via blood biomarker profiles directs specific therapies, delaying levodopa need and improving treatment precision.

Segmenting aqueous caffeine into lipid droplets via phospholipid membranes reduces release rates by twenty times compared to water.

Administering complement antagonists to naive CD4+ T cells induces FoxP3+ regulatory T cell differentiation via C3aR and C5aR signal transduction inhibition.

Specific aromatic-cationic peptide ratios overcome poor brain delivery and immunosuppressant side effects of cyclosporin A.

Retro-inverso spadin analogs resist enzymatic degradation while biodegradable copolymers provide controlled release to overcome slow onset of action.

Apoaequorin protein binds excess calcium ions to maintain homeostasis without side effects from channel antagonists.

A gastro-resistant butyrate salt formulation targets intestinal epithelial cells to modulate immune responses and reduce systemic inflammation.

MnTBAP porphyrin reverses microglial dysfunction and cognitive impairment by scavenging reactive oxygen species during acute sepsis.

Modified bacteriophage g3p polypeptides retain amyloid binding while reducing immunogenicity.

Acetate buffered polymer-G-CSF conjugate formulation maintains elevated temperature stability while reducing patient irritation from tartaric acid.

Umbilical cord-derived mesenchymal stem cell secretome increases transcription factor 4 expression to promote neural regeneration.

Small molecule proteasome enhancers restore impaired proteasome activity to clear toxic protein aggregates.

A transdermal formulation delivers curcuminoids and flavonoids to modulate enzyme activity.

Cyclic beta-hairpin peptidomimetics mimic extended substrate conformations to inhibit human neutrophil elastase.

187A5 markers isolate pure dopaminergic neuron progenitor cells, resolving the trade-off between cell purity and complex manual isolation procedures.

A carbamate compound prevents status epilepticus by targeting neuronal receptors.

Cord blood CD14+ cells improve motor function and brain connectivity by delivering neuroprotective effects to treat cerebral palsy and hypoxic-ischemic injury.

A composite pharmaceutical composition combining Sphaeranthus indicus and Garcinia mangostana extracts to regulate metabolic processes.